vs
AtriCure, Inc.（ATRC）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
ROGERS CORP的季度营收约是AtriCure, Inc.的1.4倍（$200.5M vs $140.5M），AtriCure, Inc.同比增速更快（13.1% vs 5.2%），AtriCure, Inc.自由现金流更多（$18.4M vs $1.1M），过去两年AtriCure, Inc.的营收复合增速更高（13.6% vs -3.3%）
AtriCure是一家专注于心房颤动及相关心脏病症治疗的医疗设备企业，研发并生产创新外科手术工具与疗法，主要服务北美、欧洲、亚太地区的医院、心脏外科中心及医疗机构，为微创心脏手术提供高效可靠的适配解决方案。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
ATRC vs ROG — 直观对比
营收规模更大
ROG
是对方的1.4倍
$140.5M
营收增速更快
ATRC
高出7.8%
5.2%
自由现金流更多
ATRC
多$17.3M
$1.1M
两年增速更快
ATRC
近两年复合增速
-3.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $140.5M | $200.5M |
| 净利润 | — | $4.5M |
| 毛利率 | 75.0% | 32.2% |
| 营业利润率 | 1.8% | — |
| 净利率 | — | 2.2% |
| 营收同比 | 13.1% | 5.2% |
| 净利润同比 | — | 421.4% |
| 每股收益（稀释后） | $0.04 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRCROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $140.5M | $201.5M | ||
| Q3 25 | $134.3M | $216.0M | ||
| Q2 25 | $136.1M | $202.8M | ||
| Q1 25 | $123.6M | $190.5M | ||
| Q4 24 | $124.3M | $192.2M | ||
| Q3 24 | $115.9M | $210.3M | ||
| Q2 24 | $116.3M | $214.2M |
净利润ATRCROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | — | $4.6M | ||
| Q3 25 | $-267.0K | $8.6M | ||
| Q2 25 | $-6.2M | $-73.6M | ||
| Q1 25 | $-6.7M | $-1.4M | ||
| Q4 24 | — | $-500.0K | ||
| Q3 24 | $-7.9M | $10.7M | ||
| Q2 24 | $-8.0M | $8.1M |
毛利率ATRCROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | 75.0% | 31.5% | ||
| Q3 25 | 75.5% | 33.5% | ||
| Q2 25 | 74.5% | 31.6% | ||
| Q1 25 | 74.9% | 29.9% | ||
| Q4 24 | 74.5% | 32.1% | ||
| Q3 24 | 74.9% | 35.2% | ||
| Q2 24 | 74.7% | 34.1% |
营业利润率ATRCROG
| Q1 26 | — | — | ||
| Q4 25 | 1.8% | 3.5% | ||
| Q3 25 | 0.2% | 7.3% | ||
| Q2 25 | -4.5% | -33.3% | ||
| Q1 25 | -4.8% | -0.2% | ||
| Q4 24 | -11.7% | -6.6% | ||
| Q3 24 | -6.4% | 6.9% | ||
| Q2 24 | -6.2% | 5.3% |
净利率ATRCROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | — | 2.3% | ||
| Q3 25 | -0.2% | 4.0% | ||
| Q2 25 | -4.5% | -36.3% | ||
| Q1 25 | -5.5% | -0.7% | ||
| Q4 24 | — | -0.3% | ||
| Q3 24 | -6.8% | 5.1% | ||
| Q2 24 | -6.9% | 3.8% |
每股收益（稀释后）ATRCROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.04 | $0.20 | ||
| Q3 25 | $-0.01 | $0.48 | ||
| Q2 25 | $-0.13 | $-4.00 | ||
| Q1 25 | $-0.14 | $-0.08 | ||
| Q4 24 | $-0.33 | $-0.04 | ||
| Q3 24 | $-0.17 | $0.58 | ||
| Q2 24 | $-0.17 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.4M | $195.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $491.9M | $1.2B |
| 总资产 | $654.2M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ATRCROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $167.4M | $197.0M | ||
| Q3 25 | $147.9M | $167.8M | ||
| Q2 25 | $117.8M | $157.2M | ||
| Q1 25 | $99.9M | $175.6M | ||
| Q4 24 | $122.7M | $159.8M | ||
| Q3 24 | $130.3M | $146.4M | ||
| Q2 24 | $114.0M | $119.9M |
总债务ATRCROG
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $61.9M | — | ||
| Q2 25 | $61.9M | — | ||
| Q1 25 | $61.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $61.9M | — | ||
| Q2 24 | $61.9M | — |
股东权益ATRCROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $491.9M | $1.2B | ||
| Q3 25 | $476.5M | $1.2B | ||
| Q2 25 | $464.5M | $1.2B | ||
| Q1 25 | $454.6M | $1.3B | ||
| Q4 24 | $461.0M | $1.3B | ||
| Q3 24 | $465.0M | $1.3B | ||
| Q2 24 | $462.1M | $1.3B |
总资产ATRCROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $654.2M | $1.4B | ||
| Q3 25 | $635.4M | $1.4B | ||
| Q2 25 | $608.8M | $1.5B | ||
| Q1 25 | $591.6M | $1.5B | ||
| Q4 24 | $609.3M | $1.5B | ||
| Q3 24 | $615.1M | $1.5B | ||
| Q2 24 | $597.3M | $1.5B |
负债/权益比ATRCROG
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.13× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.13× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $20.0M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $18.4M | $1.1M |
| 自由现金流率自由现金流/营收 | 13.1% | 0.5% |
| 资本支出强度资本支出/营收 | 1.1% | 2.3% |
| 现金转化率经营现金流/净利润 | — | 1.29× |
| 过去12个月自由现金流最近4个季度 | $48.3M | $70.1M |
8季度趋势，按日历期对齐
经营现金流ATRCROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $20.0M | $46.9M | ||
| Q3 25 | $26.7M | $28.9M | ||
| Q2 25 | $21.6M | $13.7M | ||
| Q1 25 | $-11.0M | $11.7M | ||
| Q4 24 | $5.8M | $33.7M | ||
| Q3 24 | $20.0M | $42.4M | ||
| Q2 24 | $7.4M | $22.9M |
自由现金流ATRCROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | $18.4M | $42.2M | ||
| Q3 25 | $24.1M | $21.2M | ||
| Q2 25 | $19.0M | $5.6M | ||
| Q1 25 | $-13.2M | $2.1M | ||
| Q4 24 | $3.1M | $18.3M | ||
| Q3 24 | $16.4M | $25.2M | ||
| Q2 24 | $5.0M | $8.8M |
自由现金流率ATRCROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | 13.1% | 20.9% | ||
| Q3 25 | 18.0% | 9.8% | ||
| Q2 25 | 13.9% | 2.8% | ||
| Q1 25 | -10.7% | 1.1% | ||
| Q4 24 | 2.5% | 9.5% | ||
| Q3 24 | 14.1% | 12.0% | ||
| Q2 24 | 4.3% | 4.1% |
资本支出强度ATRCROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 1.1% | 2.3% | ||
| Q3 25 | 1.9% | 3.6% | ||
| Q2 25 | 2.0% | 4.0% | ||
| Q1 25 | 1.8% | 5.0% | ||
| Q4 24 | 2.2% | 8.0% | ||
| Q3 24 | 3.1% | 8.2% | ||
| Q2 24 | 2.1% | 6.6% |
现金转化率ATRCROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | — | 10.20× | ||
| Q3 25 | — | 3.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | — | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATRC
| Appendage Management | $45.5M | 32% |
| Openheart | $38.5M | 27% |
| Other | $26.2M | 19% |
| Pain Management | $22.6M | 16% |
| Minimally Invasive | $7.7M | 6% |
ROG
暂无分部数据
